NCT06755632 Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C
| NCT ID | NCT06755632 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Liver Pathology |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-06-19 |
| Primary Completion | 2027-06-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2025-06-19 with a primary completion date of 2027-06-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue. Cirrhosis is a chronic disease and can get complicated by liver cancer, digestive hemorrhage, or liver failure, which are responsible for morbidity and mortality. In France, cirrhosis prevalence is estimated at 700,000 patients and induce 16,000 deaths per year (10,000 liver cancer and 6,000 liver decompensation). In Ile-de-France area, cirrhosis prevalence is estimated at 130,000 cases, a lot of them are in Seine Saint Denis department due to precariousness. Hepatitis C virus can now be cured and hepatitis B treatment can suspend hepatitis B replication. All these treatments reduce liver complications but even after virological cure, cirrhosis requires dedicated long term management as well as alcoholic liver disease and metabolic steatohepatitis at cirrhosis stage. Periodic screening for complications and specific measures were defined by french HAS in 2007 (medication intake, dietary management and specific vaccinations), especially the performance of a semi-annual liver ultrasound for hepatocellular carcinoma (HCC) screening. Then, it seems essential to screen for patients with viral hepatitis and extensive fibrosis or cirrhosis in our department to achieve active and individualized management of this chronic liver disease, to reduce long term morbidity and mortality. The main aim of the study is to evaluate the prevalence of advanced liver fibrosis and viral infections B and C in the general population of Seine Saint Denis, using a dual screening method of TROD (rapid diagnostic orientation test) and FibroScan®, combined with a care pathway
Eligibility Criteria
Inclusion Criteria: * Age≥18 years * Collection of signed consent * Patients affiliated to a Social Security System Exclusion Criteria: * Pregnancy or breastfeeding * Subjects under AME * Persons under court protection * Guardianship or curatorship, * Safeguard of justice * Persons under psychiatric care without their consent * Persons admitted to a health or social institution for purposes other than research, * Patients of full age under legal protection (guardianship or curatorship) * Persons unable to express their consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06755632 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Pathology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755632 currently recruiting?
Yes, NCT06755632 is actively recruiting participants. Contact the research team at veronique.grando@aphp.fr for enrollment information.
Where is the NCT06755632 trial being conducted?
This trial is being conducted at Bobigny, France, Bobigny, France.
Who is sponsoring the NCT06755632 clinical trial?
NCT06755632 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 600 participants.